Cenduit IRT currently provides randomization and trial supply management for the world’s largest precision medicine trial to investigate treatment for non-small cell lung cancer. This trial is investigating genetic biomarker targeted therapy combinations, via partnership between non-profit research organizations and large pharmaceutical companies.
Trial design for this type of study presents unique challenges. These include the need for an IRT platform that can support the rapid incorporation of amendments and account for multiple or potential arms which require different lists of material types and dosages that could be prescribed to patients and supplied to sites. Cenduit’s highly-configurable, flexible technology platform was the solution.